AUTHOR=Burton Charles P. , Chumin Evgeny J. , Collins Alyssa Y. , Persohn Scott A. , Onos Kristen D. , Pandey Ravi S. , Quinney Sara K. , Territo Paul R. 

TITLE=Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer’s disease

JOURNAL=Frontiers in Neuroscience

VOLUME=Volume 17 - 2023

YEAR=2024

URL=https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1336026

DOI=10.3389/fnins.2023.1336026

ISSN=1662-453X

ABSTRACT=is an FDA approved anti-convulsant and is currently under clinical trials in AD patients. In this manuscript, Burton et al. studied brain metabolic networks and transcriptomic signatures in 5XFAD mice after the treatment of LEV. It was found that there were significant dose-dependent changes in region-wise glycolytic correlation and gene expression changes in response to LEV. Overall, this study is novel and interesting, providing translational value towards informing clinical study design.Comments: 1. In Methods section, it was stated that LEV was given via oral gavage for chronic studies in 5xFAD mice, but there is no information on administration route in LEV PK studies.